Levaquin Class Action Lawsuit (also known as Latent-Vault) is one of the most widely-known peripheral neuropathy lawsuits in the United States. It involves a case that went to trial in Federal Court in Miami-Dade County. The plaintiff’s lawyer, Levaquin attorney; Jose Velasco, alleged that his client suffered nerve damage after taking a medication called Relorx. According to Velasco, the drug had no therapeutic value and was instead a “medical scam.” The defendant, Relorx Corp., did not admit any wrongdoing but agreed to pay a fine of about $15 million to the plaintiffs.
Levaquin Class Action Lawsuit
Neuropathy causes certain nerves to become damaged, which results in numbness or tingling. In this case, Levaquin attorneys alleged that Velasco’s client had a reaction to the drug’s side effects. As a result, he suffered severe leg injuries. Velasco subsequently developed Levaquin as a result of taking the contaminated medication. His lawyers alleged that the company failed to warn him of the possible side effects and did not instruct him on how to use the product.
Velasco’s lawyers alleged that Levaquin failed to warn him of its risks and that he was exposed to harmful toxins during his use of Relorx. The FDA determined that the company complied with all of the regulations regarding proper labeling and did notify the plaintiff that it contained an ingredient that could cause peripheral neuropathy. It was also determined that the product was appropriate for use by anyone age 12 or older. However, Levaquin did not include a black box warning, which is required under the FDA’s labeling regulations. This class action lawsuit against Levaquin Corp. also included a claim for negligence.
There has been a number of recent studies involving Levaquin. A recent study published in the Journal of American Science showed that Levaquin increased the risk of developing severe allergic reactions in patients who took the antibiotic for a longer period of time. This new evidence prompted Levaquin’s manufacturers to file a class action lawsuit against the company, and they are seeking damages for Levaquin’s “fatal” side effects. The manufacturers of Levaquin now indicate that they will seek compensation from users of Levaquin for those who have experienced serious adverse reactions to this drug.
According to recent studies, Levaquin does not promote the growth of heart disease, as had been previously thought. However, it can cause a condition known as “ischemia,” which occurs when the brain stem cells become abnormal. This condition can result in a condition in which the heart pumps insufficient blood to supply to the brain. This can result in a condition known as “ischemia gravis,” in which a patient can suffer from a stroke or heart attack. The lawsuit against GlaxoSmithKline acknowledges that Levaquin’s ingredients cause these side effects, but does not directly admit or deny that these side effects were caused by the use of Levaquin.
These recent studies come at a time when Levaquin is undergoing regulatory trials for potential new uses. Levaquin has been approved for short-term use to treat infections in the upper gastrointestinal tract and has been shown to be effective in the treatment of infectious mononucleosis and herpes. However, Levaquin has shown little benefit in treating acute infectious mononucleosis or infectious endocarditis, and these recent studies may change the way doctors prescribe or recommend the medication.
